Skip to main content
Mérieux Equity Partners
Link Header
  • Investor Access
  • English
  • French
Menu
Main navigation
  • About Us
    • Invested Investors
    • Venture Capital
    • Growth / Buyout
    • Key Figures
    • AMF Regulation
  • Our People
  • Our Portfolio
  • ESG
  • News
  • Meet Us
Breadcrumb
  1. Accueil
  2. News List
  3. Ginkgo Bioworks Adopts INSCRIPTA’s Onyx Digital Genome Engineering Platform
Image
illustration
Venture Capital News

Ginkgo Bioworks Adopts INSCRIPTA’s Onyx Digital Genome Engineering Platform

Monday 10 January, 2022
Body

Ginkgo’s investment is part of its commitment to integrating cutting-edge technology into its foundries as it aims to increase the performance and productivity of its metabolic and protein engineering workflow and grow its pipeline.

Content

Download

  • Press Release
    Download
Related News
  • Mimetas
    2022-04-14

    MIMETAS participates in €325 M Oncode-PACT initiative to accelerate and improve oncology drug development

    The goal of Oncode-PACT is to create a state-of-the-art drug development infrastructure to innovate the cancer drug development process itself.

  • Tara Biosystems
    2022-04-05

    Valo Health acquires TARA BIOSYSTEMS creating first of its kind vertically integrated cardiovascular platform

    TARA's state-of-the-art in vitro human cardiac disease models combined with Valo's artificial intelligence-driven Opal platform – which is built on...

  • Cairdac
    2022-03-31

    CAIRDAC’s completes first Serie A funding of €17 M to develop ALPS - the world’s first self-sustainable leadless pacemaker

    It is the first time in the industry that a self-contained implantable medical device is capable of generating its own energy when operated.

Mérieux Equity Partners

Follow Us
  • Linked In
Footer
  • Legal mentions
ⓒ Insign